Annexon grants options to new employees, advancing therapies for neuroinflammatory diseases

From “GlobeNewswire”: 2024-06-17 16:05:00

Annexon, Inc. granted inducement to two new non-executive employees under the 2022 Employment Inducement Award Plan, giving them options to purchase 109,300 shares of company stock with a ten-year term and an exercise price of $5.62. These options will vest over 4 years, starting with 25% on the first anniversary of the grant date. The company, a biopharmaceutical advancing therapies for complement-mediated neuroinflammatory diseases, targets C1q to prevent inflammatory cascades in autoimmune, neurodegenerative, and ophthalmic conditions. Proof-of-concept data in diseases like Guillain-Barré syndrome and Huntington’s disease is leading to mid- to late-stage clinical trials for potential treatments.



Read more at “GlobeNewswire”: Annexon Reports Inducement Grants to New Employees Under